SOLENO THERAPEUTICS INCSLNOEarnings & Financial Report
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
SLNO Q3 FY2025 Key Financial Metrics
Revenue
$66.0M
Gross Profit
$64.9M
Operating Profit
$22.1M
Net Profit
$26.0M
Gross Margin
98.3%
Operating Margin
33.5%
Net Margin
39.4%
YoY Growth
N/A
EPS
$0.47
SOLENO THERAPEUTICS INC Q3 FY2025 Financial Summary
SOLENO THERAPEUTICS INC reported revenue of $66.0M for Q3 FY2025, with a net profit of $26.0M (up 134.0% YoY) (39.4% margin). Cost of goods sold was $1.1M, operating expenses totaled $42.8M.
Key Financial Metrics
| Total Revenue | $66.0M |
|---|---|
| Net Profit | $26.0M |
| Gross Margin | 98.3% |
| Operating Margin | 33.5% |
| Report Period | Q3 FY2025 |
SOLENO THERAPEUTICS INC Quarterly Revenue & Net Profit History
SOLENO THERAPEUTICS INC results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $66.0M | — | $26.0M | 39.4% |
| Q2 FY2025 | $32.7M | — | $-4.7M | -14.4% |
Income Statement
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Revenue | $32.7M | $66.0M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Assets | $332.3M | $599.9M |
| Liabilities | $92.2M | $105.1M |
| Equity | $240.1M | $494.8M |
Cash Flow
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Operating CF | $-12.6M | $43.5M |